Recent

% | $
Quotes you view appear here for quick access.

OCATA THERAPEUTICS, INC. Message Board

  • lizdan_7 lizdan_7 Jan 8, 2013 7:50 PM Flag

    Anyone else look at presentaion today

    I went to the ACTC website looked under Biotech Showcase San Francisco Calif Jan 8Th 2013

    Below is slid Number 24 and 25.

    Preliminary Results – Functional 24 Visual Acuity Measurements
    •SMD Patient: BCVA improved from hand motions to 20/800 and improved from 0 to 5 letters on the ETDRS visual acuity chart
    •Dry AMD Patient: Vision improved in the patient with dry age-related macular degeneration (21 ETDRS letters to 28) 14 month Follow-up:
    •Visual acuity gains remain relatively stable for both patients
    •SMD Patient continues to show improvement. U.K. SMD01 Patient (at 9 month follow-up)
    •ETDRS: Improved from 5 letters to 10 letters, and stable
    •Subjective: Reports significantly improved ability to read text on TV

    Current Safety Profile – Stargardt’s Trial 25 12 SMD Patients Treated 3 patients (50K cells cohort) treated – US Trial Cohort Complete 3 patients (50K cells cohort) treated – UK Trial Cohort Complete 3 patient (100K cells cohort) treated – US Trial Cohort Complete 3 patient (100K cells cohort) treated – UK Trial Cohort Complete No reports of any adverse events or complications due to cells per se
    •No evidence of inflammation or infiltration
    •No evidence of ectopic tissue formation
    •No evidence of retinal detachment

    Looking Good

    Always do as you feel,
    Not what you hear

    Happy investing at all Sellers and Buyers.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies